{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:42:19Z","timestamp":1790754139525,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.therap.2018.01.007","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T14:07:50Z","timestamp":1519740470000},"page":"419-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Consommation de substances psychoactives \u00e0 la R\u00e9union et \u00e0 Mayotte, d\u00e9partements fran\u00e7ais de l\u2019Oc\u00e9an Indien"],"prefix":"10.1016","volume":"73","author":[{"given":"Am\u00e9lie","family":"Daveluy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Haramburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2018.01.007_bib0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/fcp.12233","article-title":"Which psychoactive substances are used by patients seen in the health care system in French overseas territories? Results of the OPPIDUM survey","volume":"31","author":"Daveluy","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.01.007_bib0155","series-title":"Tableau de bord sur les addictions \u00e0 La R\u00e9union","author":"Observatoire r\u00e9gional de sant\u00e9 Oc\u00e9an Indien","year":"2011"},{"key":"10.1016\/j.therap.2018.01.007_bib0160","series-title":"Tableau de bord sur les addictions \u00e0 La R\u00e9union","author":"Observatoire r\u00e9gional de sant\u00e9 Oc\u00e9an Indien","year":"2015"},{"key":"10.1016\/j.therap.2018.01.007_bib0165","series-title":"Rapport de l\u2019Organe international de contr\u00f4le des stup\u00e9fiants pour 2014","author":"OICS","year":"2015"},{"key":"10.1016\/j.therap.2018.01.007_bib0170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2515\/therapie\/2009054","article-title":"Second meeting of the French CEIP (Centres d\u2019\u00e9valuation et d\u2019information sur la pharmacod\u00e9pendance). Part I: how to evaluate and prevent the abuse and dependence on hypnotic\/anxiolytic drugs?","volume":"64","author":"Micallef-Roll","year":"2009","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.01.007_bib0175","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/fcp.12024","article-title":"OPPIDUM surveillance program: 20\u00a0years of information on drug abuse in France","volume":"27","author":"Frauger","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.01.007_bib0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.01.007_bib0185","unstructured":"Institut national de la statistique et des \u00e9tudes \u00e9conomiques. 2018. http:\/\/www.insee.fr [consult\u00e9 le 22\u00a0f\u00e9vrier 2018]."},{"key":"10.1016\/j.therap.2018.01.007_bib0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.revmed.2016.07.003","article-title":"Une maladie au traitement hautement compulsif","volume":"38","author":"Raffray","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2018.01.007_bib0195","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2515\/therapie:2003088","article-title":"Misuse of trihexyphenidyl (Artane, Parkinane): recent trends","volume":"58","author":"Frauger","year":"2003","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.01.007_bib0200","first-page":"129","article-title":"L\u2019usage d\u00e9tourn\u00e9 de trihexyph\u00e9nidyle","volume":"30","author":"M\u00e9t\u00e9","year":"2008","journal-title":"Alcool Addictol"},{"key":"10.1016\/j.therap.2018.01.007_bib0205","series-title":"Commission de la transparence. Artane\u00ae, avis","author":"Haute autorit\u00e9 de sant\u00e9 (HAS)","year":"2012"},{"key":"10.1016\/j.therap.2018.01.007_bib0210","series-title":"\u00c9valuation du potentiel d\u2019abus et de dependance de l\u2019Artane\u00ae (trih\u00e9xyph\u00e9nidyle) et des antiparkinsoniens anticholinergiques. Commission nationale des stup\u00e9fiants et psychotropes","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9","year":"2012"},{"key":"10.1016\/j.therap.2018.01.007_bib0215","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jps.2600770905","article-title":"Pharmacokinetic evaluation of a sustained-release formulation of trihexyphenidyl in healthy volunteers","volume":"77","author":"Cheung","year":"1988","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.therap.2018.01.007_bib0220","first-page":"231","article-title":"\u00c9tude pharmacocin\u00e9tique comparative de deux formes gal\u00e9niques de trihexyph\u00e9nidyle dos\u00e9es a 5mg\u00a0: comprim\u00e9s (Artane\u00ae) et g\u00e9lules \u00e0 lib\u00e9ration progressive (Parkinane retard\u00ae)","volume":"39","author":"Devissaguet","year":"1984","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.01.007_bib0225","series-title":"Usage d\u00e9tourn\u00e9 de m\u00e9dicaments antitussifs et antihistaminiques chez les adolescents et les jeunes adultes \u2013\u00a0Point d\u2019Information","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)","year":"2016"},{"key":"10.1016\/j.therap.2018.01.007_bib0230","series-title":"Risques d\u2019abus, de m\u00e9susage et de pharmacod\u00e9pendance li\u00e9s \u00e0 l\u2019utilisation de la pr\u00e9gabaline (Lyrica et g\u00e9n\u00e9riques) \u2013\u00a0point d\u2019information","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)","year":"2016"},{"issue":"6","key":"10.1016\/j.therap.2018.01.007_bib0235","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.therap.2016.04.006","article-title":"Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history","volume":"71","author":"Driot","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.01.007_bib0240","unstructured":"Balicchi J, Bini JP, Daudin V, Actif N, Rivi\u00e8re J, direction r\u00e9gionale La R\u00e9union-Mayotte. Mayotte, d\u00e9partement le plus jeune de France. Insee Premi\u00e8re no\u00a01488. F\u00e9vrier 2014. http:\/\/www.insee.fr\/fr\/statistiques\/fichier\/1281384\/ip1488.pdf, [consult\u00e9 le 3\u00a0janvier 2018]."},{"key":"10.1016\/j.therap.2018.01.007_bib0245","series-title":"Compte-rendu de la mission conduite par Mme Yvette Mathieu, Pr\u00e9f\u00e8te, Charg\u00e9e de mission aupr\u00e8s du D\u00e9fenseur des droits, sur la protection des droits de l\u2019enfant \u00e0 Mayotte, Paris","author":"Le d\u00e9fenseur des droits","year":"2013"},{"key":"10.1016\/j.therap.2018.01.007_bib0250","unstructured":"Pr\u00e9fet de Mayotte. Plan d\u00e9partemental de pr\u00e9vention et de lutte contre l\u2019illettrisme et l\u2019analphab\u00e9tisme \u00e0 Mayotte, 2011\u20132015. N.D. http:\/\/www.irtsreunion.fr\/IMG\/file\/schemas\/Mayotte_planIllettrisme2011-2015.pdf [consult\u00e9 le 22\u00a0f\u00e9vrier 2018]."},{"key":"10.1016\/j.therap.2018.01.007_bib0255","series-title":"La d\u00e9mographie m\u00e9dicale en r\u00e9gion DOM-TOM. Situation en 2013","author":"Ordre national des m\u00e9decins","year":"2013"},{"key":"10.1016\/j.therap.2018.01.007_bib0260","series-title":"\u00c0 Mayotte, l\u2019affaire qui embarasse les gendarmes","author":"Le Point","year":"2015"},{"key":"10.1016\/j.therap.2018.01.007_bib0265","first-page":"18","article-title":"The emergence of synthetic cannabinoids in Mayotte","volume":"27","author":"Roussel","year":"2015","journal-title":"Toxicol Anal Clin"},{"key":"10.1016\/j.therap.2018.01.007_bib0270","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.therap.2016.11.012","article-title":"Profil m\u00e9dico-social des patients ayant consult\u00e9 au Centre d\u2019addictologie de Mayotte en 2015\u00a0pour usage de nouveaux produits de synth\u00e8se, une \u00e9tude r\u00e9trospective","volume":"72","author":"Fleury","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.01.007_bib0275","series-title":"Soup\u00e7onn\u00e9 de trafic de \u00ab\u00a0chimique\u00a0\u00bb, le fonctionnaire du d\u00e9partement reste en prison","author":"Le Journal de Mayotte","year":"2016"},{"key":"10.1016\/j.therap.2018.01.007_bib0280","series-title":"Mayotte\u00a0: 16\u00a0principaux dealers de la drogue de synth\u00e8se dite \u00ab\u00a0chimique\u00a0\u00bb sous les verrous","author":"FMayotte 1\u00e8re","year":"2016"},{"key":"10.1016\/j.therap.2018.01.007_bib0285","series-title":"Recrudescence de passages li\u00e9s \u00e0 la consommation de cannabino\u00efdes de synth\u00e8se \u00ab\u00a0la chimique\u00a0\u00bb dans le service d\u2019urgences du centre hospitalier de Mayotte, 2012\u20132016. Bulletin de veille sanitaire oc\u00e9an Indien","author":"Vilain","year":"2017"},{"key":"10.1016\/j.therap.2018.01.007_bib0145","series-title":"Bangu\u00e9 \u00ab\u00a0mangrove\u00a0\u00bb\u00a0: interpellation d\u2019un vendeur. \u00c0 c\u00f4t\u00e9 des locaux de la police","author":"Le journal de Mayotte","year":"2015"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718300374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718300374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:52:33Z","timestamp":1758567153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718300374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0040595718300374"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.01.007","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consommation de substances psychoactives \u00e0 la R\u00e9union et \u00e0 Mayotte, d\u00e9partements fran\u00e7ais de l\u2019Oc\u00e9an Indien","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}